Anti-inflammatory effects of free and liposome-encapsulated Algerian thermal waters in RAW 264.7 macrophages

Mokdad, Romaissaa; Seguin, Cendrine; Fournel, Sylvie; Frisch, Benoı̂t; Heurtault, Béatrice; Hadjsadok, Abdelkader

doi:10.1016/j.ijpharm.2022.121452

Cited by 7 publications

(3 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data demonstrated that CDP-choline/OX26Lip have suitable physicochemical properties for in vivo administration and brain targeting, i.e. an average diameter below 100 nm [47] , a net negative Z-potential value with suitable electrostatic repulsion between vesicles in suspension [48,49] , a narrow size distribution [50] and the presence of OX26 targeting molecules on the liposomal surface [35] . Namely, the conjugation of OX26 to liposomes, as well as their average sizes below the cut-off of brain vasculature fenestration during ischemic process, promotes the liposome targeting into the brain following their in vivo administration [18,51] .…”

Section: Physicochemical Characterizationmentioning

confidence: 80%

OX26-cojugated gangliosilated liposomes to improve the post-ischemic therapeutic effect of CDP-choline

d'Avanzo,

Paolino,

Barone

et al. 2024

Preprint

View full text Add to dashboard Cite

Cerebrovascular impairment still represents one of the main causes of death worldwide with a mortality rate of 5.5 million per year. Furthermore, the disability of 50% of surviving patients represents a factor with both a high social impact and high costs for long periods of time for national healthcare systems. For these reasons, the efficacious clinical treatment of patients suffering of a brain ischemic stroke is still a medical need. To this aim, a liposome nanomedicine having monosialic ganglioside type 1 (GM1) between its constituent and bearing OX26 (an anti-transferrin receptor antibody) was prepared by entrapping CDP-choline (a neurotrophic drug) (CDP-choline/OX26Lip), characterized and tested in vivo on an ischemic rat model. CDP-choline/OX26Lip were prepared by a freeze and thaw followed by extrusion through polycarbonate filters, thus achieving ~80 nm mean size and a homogeneous size distribution. It was demonstrated that CDP-choline/OX26Lip showed a suitable stability in the presence of human serum. CDP-choline/OX26Lip showed also a suitable pharmacokinetic profile, having 30.0±4.2 % of the administered dose in the blood stream 12 h after its systemic administration. The post-ischemic therapeutic effect of CDP-choline/OX26Lip is better than CDP-choline/Lip, thus showing a significant greater survival rate of re-perfused post-ischemic rats, i.e. 96% and 78% after 8 days, respectively. The treatment with CDP-choline/OX26Lip significantly decreased the peroxidation rate of almost 5-fold compared to CDP-choline/Lip, as expressed in amount of conjugated dienes,i.e. 13.9 ± 1.1 and 3.1 ± 0.8 mmol/mg proteins, respectively. The increased therapeutic effect could be attributed to the improved accumulation of the encapsulated CDP-choline delivered by the OX26-conjugated GM1-liposomes. Therefore, this nanomedicine may represent a suitable strategy for the reassessment of CDP-choline as a line option in the therapeutic treatment of post-ischemic events caused by brain stroke, thus responding to significant clinical needs.

show abstract

Section: Physicochemical Characterizationmentioning

confidence: 80%

OX26-cojugated gangliosilated liposomes to improve the post-ischemic therapeutic effect of CDP-choline

d'Avanzo,

Paolino,

Barone

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Among the nanosystems used as CRSs, liposomes stand out [ 18 ]. Due to their amphiphilic nature, the encapsulation of drugs in liposomes protects them from physiological degradation [ 19 , 20 , 21 ]. However, liposomes are sensitive to stomach pH.…”

Section: Introductionmentioning

confidence: 99%

Ceftazidime and Usnic Acid Encapsulated in Chitosan-Coated Liposomes for Oral Administration against Colorectal Cancer-Inducing Escherichia coli

de Souza,

de Lacerda Coriolano,

dos Santos Silva

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Escherichia coli has been associated with the induction of colorectal cancer (CRC). Thus, combined therapy incorporating usnic acid (UA) and antibiotics such as ceftazidime (CAZ), co-encapsulated in liposomes, could be an alternative. Coating the liposomes with chitosan (Chi) could facilitate the oral administration of this nanocarrier. Liposomes were prepared using the lipid film hydration method, followed by sonication and chitosan coating via the drip technique. Characterization included particle size, polydispersity index, zeta potential, pH, encapsulation efficiency, and physicochemical analyses. The minimum inhibitory concentration and minimum bactericidal concentration were determined against E. coli ATCC 25922, NCTC 13846, and H10407 using the microdilution method. Antibiofilm assays were conducted using the crystal violet method. The liposomes exhibited sizes ranging from 116.5 ± 5.3 to 240.3 ± 3.5 nm and zeta potentials between +16.4 ± 0.6 and +28 ± 0.8 mV. The encapsulation efficiencies were 51.5 ± 0.2% for CAZ and 99.94 ± 0.1% for UA. Lipo-CAZ-Chi and Lipo-UA-Chi exhibited antibacterial activity, inhibited biofilm formation, and preformed biofilms of E. coli. The Lipo-CAZ-UA-Chi and Lipo-CAZ-Chi + Lipo-UA-Chi formulations showed enhanced activities, potentially due to co-encapsulation or combination effects. These findings suggest potential for in vivo oral administration in future antibacterial and antibiofilm therapies against CRC-inducing bacteria.

show abstract

“…What’s more, many complex liposomes have been designed and prepared, such as ligand-targeted liposomes ( Lv et al, 2018 ), and triggered release liposomes ( Zhang et al, 2018 ; Ansari et al, 2021 ). Although they were not applied in the clinic now, these advances led to numerous clinical trials and more potential applications in the delivery of anti-cancer ( Cao et al, 2016 ; Kiaie et al, 2020 ), anti-biotic ( Shen et al, 2022 ), anesthetics ( Ruokonen et al, 2017 ), and anti-inflammatory drugs ( Mokdad et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

OEA loaded liposomes with the neuroprotective effect for stroke therapy

Yang

2022

Front. Chem.

View full text Add to dashboard Cite

With high mortality, stroke has become a serious threat to human health. Nevertheless, the strategy for stroke therapy is quite limited in the clinic till now. In this research, we prepared a novel neuroprotective nanoformulation (OEA Liposomes) via encapsulating endogenous N-oleoylethanolamine (OEA) in liposomes for intravenous administration. The formulation largely increased the solubility and bioavailability of OEA. Then the following systematic experiments stated the excellent neuroprotective effect of OEA Liposomes in vivo. The survival rate of the nanodrug group was largely increased to 75%, while that of the Middle Cerebral Artery Occlusion (MCAO) group was only 41.7%. And the severe neurological functional deficit of the MCAO rats was also significantly improved. What’s more, the OEA Liposomes could inhibit the apoptosis of neurons and the inflammation of reperfusion to a very slight level, indicating their outstanding neuroprotective effect. These results indicated that the OEA Liposomes have a great potential for clinic anti-stroke application.

show abstract

Anti-inflammatory effects of free and liposome-encapsulated Algerian thermal waters in RAW 264.7 macrophages

Cited by 7 publications

References 69 publications

OX26-cojugated gangliosilated liposomes to improve the post-ischemic therapeutic effect of CDP-choline

OX26-cojugated gangliosilated liposomes to improve the post-ischemic therapeutic effect of CDP-choline

Ceftazidime and Usnic Acid Encapsulated in Chitosan-Coated Liposomes for Oral Administration against Colorectal Cancer-Inducing Escherichia coli

OEA loaded liposomes with the neuroprotective effect for stroke therapy

Contact Info

Product

Resources

About